Medical Oncologist
When treatment stops working
Primary vs Acquired Resistance: — Two Very Different Problems
Being told that treatment is no longer working is one of the most frightening moments in a cancer journey. The first thing your oncologist needs to establish is whether the cancer never responded, or whether it responded and then stopped — because those two situations lead to very different next steps.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Two distinct situations — Primary and acquired resistance have different biological causes and require different responses.
- Biology explains it — Resistance almost always comes down to genetic changes — either already present in the tumour, or developed under treatment pressure.
- Retesting often comes first — A repeat biopsy or liquid biopsy can show what has changed, and that information guides the next decision.
- Next lines exist — Resistance confirms that one treatment has stopped helping. It does not close all options.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Primary resistance means your cancer did not respond from the start of treatment. Acquired resistance means it responded at first, then started growing again. They are different biological events. Your oncologist uses scan results — and sometimes a repeat biopsy — to tell them apart, and that distinction shapes which next treatment is most likely to help.
Why did the treatment not work at all from the start?
When a treatment has no effect from the very first scan, this is called primary resistance. The cancer was already equipped — before you started — with a way to survive that particular treatment.
This happens because some cancer cells carry a mutation or an active survival pathway that the drug cannot block. Targeted therapies and immunotherapies are especially vulnerable to this, because they work by hitting one specific target — and if that target is absent, altered, or bypassed, the drug has nothing to act on.
Biomarker testing before treatment is designed to reduce this risk. If the right marker is found, treatment is more likely to help. But markers are not perfect predictors, and primary resistance can still occur even when the initial test result looked favourable.
What do terms like primary and acquired resistance actually mean?
- Primary resistance
- The cancer does not shrink or stabilise when a new treatment begins. Scans at the first assessment after starting show growth or no meaningful change.
- Acquired resistance
- The cancer initially responds — it shrinks or stabilises — then, over months or years, starts growing again while the same treatment continues.
- Cross-resistance
- When resistance to one drug also blocks related drugs in the same family, because the tumour uses the same biological escape route against all of them.
- Clonal evolution
- Cancer is not one identical population of cells. A small group that already carries a resistant mutation can survive treatment, replicate, and eventually become the dominant population — this is how most acquired resistance develops.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
How does cancer learn to resist a treatment that was working?
Cancer cells divide rapidly and accumulate mutations. When treatment kills the sensitive cells, those that survive are the ones that already had — or happen to develop — a way to escape.
Over time, these resistant cells multiply and become the dominant population. A scan that once showed shrinkage begins to show growth again. This is not a mistake — it is clonal evolution under selection pressure.
ESMO and ASCO guidance for several cancer types now recommends a repeat biopsy — or a liquid biopsy drawn from blood — when acquired resistance is suspected. The aim is to identify which new mutation or pathway is driving growth, because that determines which next-line treatment has the strongest rationale.
What happens next when resistance is confirmed?
The answer depends on which kind of resistance it is, what the rebiopsy shows, and what treatments you have already received.
For primary resistance, the approach is usually to move to a different drug class or a different treatment strategy altogether — sometimes chemotherapy after a targeted therapy has not worked, sometimes a clinical trial testing a new agent.
For acquired resistance, the biology of what changed matters most. In some cancers, a second-generation drug targeting the same pathway — but designed to work despite the new mutation — is available. In others, the resistance mechanism points toward a different combination, a different target, or a clinical trial.
Your oncologist will review what is known, what is currently available, and whether any trials are open that suit your situation. Asking explicitly for that review is a reasonable and expected part of the conversation after a resistance diagnosis.
What families want to know when resistance is confirmed
Does resistance mean there are no more options?
Resistance means one specific treatment is no longer working — it does not mean all options are exhausted. Most patients who develop resistance go on to receive further treatment, whether a different drug, a different combination, or a clinical trial. The number and type of further options depends on your cancer type, the treatments you have already had, and your general health. The right question to ask is not whether options exist, but which are most appropriate now. Your oncologist can map those out for your specific situation.
Should we ask for a repeat biopsy when treatment stops working?
In many cases, yes — and ESMO and ASCO guidelines for several cancer types recommend it. A repeat biopsy or liquid biopsy can show what has changed in the tumour since you were first diagnosed. That information may reveal a new mutation that can be targeted, or a resistance mechanism that rules out certain drugs and points clearly toward others. Not every situation requires one — your oncologist will tell you whether a repeat sample is likely to change the treatment plan, and whether tissue or blood biopsy is more appropriate.
Can the same drug ever work again after a break from it?
In a small number of situations, yes. Some cancers that developed resistance to a drug can regain sensitivity after a period off that treatment — particularly if the resistant cells are less fit than the original population and decline without the selection pressure that treatment creates. This is not a common strategy and does not apply to most cancers or most drugs. Your oncologist will tell you whether re-challenge is a recognised approach for your cancer type. Do not stop or restart treatment based on what you have read — ask your team first.
What is a clinical trial and is it worth considering?
A clinical trial tests a drug or combination that is not yet part of standard treatment. When standard options after resistance are limited, a trial can offer access to treatments that are otherwise unavailable. Joining one does not mean being a test subject in a risky sense — trials in India require CDSCO approval, and eligibility criteria are designed to protect participants. Ask your oncologist whether any trials are open at your centre, or at a centre you can travel to. Being enrolled in a trial is not a last resort — it is sometimes the best available option.
Does acquired resistance always develop eventually?
For most targeted therapies, acquired resistance develops in a proportion of patients over time — though the timeline varies considerably. Some responses hold for many months before resistance develops; others last much longer. Immunotherapy responses tend to be more durable, but resistance still occurs in a proportion of patients. The pace of resistance is one of the things your oncologist monitors at each scan, and it informs how urgently the next decision needs to be made and which options remain viable.
We heard about tumour heterogeneity. Does it make resistance harder to treat?
Tumour heterogeneity means different parts of the same cancer can carry different genetic profiles. This matters for resistance because a drug may eliminate one population of cells while a different subpopulation — which already carries a resistance mechanism — survives and takes over. It is one of the reasons a single biopsy does not always capture the full picture. Newer approaches, including liquid biopsy and multi-region sampling, are aimed partly at this problem. We do not yet have a complete answer to heterogeneity-driven resistance, and your oncologist will tell you honestly what is and is not known for your cancer type.
Explore 39 more Monitoring, Resistance & Long-Term Response topics
Resistance, Progression & Next Lines
- Being Told 'There Are No More Options': Is That Really True?
- Brain Metastases on Targeted Therapy: Does Your Drug Reach the Brain?
- Can You Continue the Same Drug After Progression?
- Combination Therapy to Overcome Resistance
- Do You Need Another Biopsy When the Cancer Progresses?
- Histologic Transformation: When Lung Cancer Changes Type
- How to Emotionally Process a Progression Scan
- Leptomeningeal Disease: Symptoms, Diagnosis and Treatment
- Life After ALK Inhibitor Resistance: Sequencing Your Options
- MET Amplification and Other Bypass Resistance Mechanisms
- Oligoprogression: When Only One or Two Spots Grow
- Primary vs Acquired Resistance: Two Very Different Problems
- Should You Change Hospitals After Progression?
- What Happens After Osimertinib Stops Working?
- What Is Sequencing and Why the Order of Drugs Matters
- Why Does Targeted Therapy Stop Working? The Biology of Resistance
Long-Term Response, Stopping & Survivorship
- Am I Still a Cancer Patient? Identity After Long-Term Response
- Bone Health, Heart Health and Late Effects to Monitor
- Can You Ever Stop Targeted Therapy If the Cancer Is Gone?
- Drug Holidays: Are Planned Breaks Safe?
- Follow-Up Schedule After Stopping Targeted Therapy
- How Long Do You Have to Stay on Targeted Therapy?
- Long-Term Effects of Taking a TKI for 5 or 10 Years
- Restarting Treatment After a Break
- Treatment-Free Remission in CML: Who Can Stop Their TKI?
- Your Survivorship Care Plan: What Should Be In It
Monitoring, Scans & Response Assessment
- Are Tumour Markers Reliable on Targeted Therapy?
- Complete Response, Partial Response, Stable Disease: What Each Means
- Do I Need Regular Brain MRIs on Targeted Therapy?
- How Doctors Measure Whether Targeted Therapy Is Working
- How Often Will I Need Scans on Targeted Therapy?
- How to Read a CT or PET Scan Report Without Panicking
- Is 'Stable Disease' Good News or Bad News?
- Scanxiety: How to Get Through the Wait for Scan Results
- Tumour Flare and Pseudoprogression: When Growth Isn't Really Growth
- Understanding PFS, OS and Median Survival Without Losing Hope
- What Happens at a Follow-Up Visit: A Walk-Through
- Which Blood Tests Are Repeated Every Month and Why
- ctDNA Monitoring: Can a Blood Test Predict Progression Early?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How does the doctor know whether it is primary or acquired resistance?
The distinction is established by comparing what your scans showed at the first assessment after starting treatment with what they show now. If the cancer grew or never changed from the very first evaluation, that points to primary resistance. If it shrank or stabilised first and only later started growing again, that is acquired resistance. Your oncologist will review the timeline of your scan results alongside the clinical picture to make this determination — you can ask them directly which category applies to you.
Does resistance to a targeted therapy mean chemotherapy is the only next step?
Not necessarily. In some cancers, a second-generation targeted therapy exists that works despite the resistance mutation — certain lung cancers are one example, where later-generation inhibitors can target the same pathway differently. In other situations, immunotherapy, a different combination, or a clinical trial may be more appropriate. The right next step depends on your cancer type, the resistance mechanism identified, and what you have already received. Your oncologist will explain which applies to your situation.
Can emerging resistance be detected before it shows on a scan?
Liquid biopsy — a blood test that detects fragments of tumour DNA circulating in the blood — is increasingly used to monitor for resistance mutations before they become visible on imaging. This is available in India through specialist centres and select laboratories, though it is not yet part of routine monitoring for all cancer types. ESMO supports its use in some settings. Ask your oncologist whether liquid biopsy monitoring is applicable to your cancer type and available at your treating centre.
Is there anything that can prevent resistance from developing?
There is no fully reliable way to prevent resistance, and ASCO and ESMO acknowledge this openly. Some treatment strategies — such as combination therapy, which makes it harder for a single mutation to bypass all the drugs at once — are designed to delay resistance rather than prevent it entirely. We do not yet have a way to predict reliably which patients will develop resistance or when. This is an active area of research, and clinical trials are exploring approaches specifically aimed at overcoming and delaying it.
Should we seek a second opinion when treatment stops working?
A second opinion is always reasonable, and most oncologists support it. When a treatment stops working, the case often becomes more complex, and review by a specialist with particular expertise in your cancer type can sometimes identify options that were not previously available or considered. At CION, you can ask your treating oncologist about a multidisciplinary team review, which brings multiple specialists together to evaluate the same case and discuss next steps.
What should we ask at the next appointment after resistance is confirmed?
Ask four things: whether this is primary or acquired resistance and what that means for your specific situation; what a repeat biopsy might add; which next-line treatments are available and recommended for your cancer type and stage; and whether any clinical trials are open that you are eligible for. Writing the answers down helps — these conversations are difficult to retain when you are frightened. It is entirely reasonable to ask for a follow-up appointment once you have had time to take it in.